

Constantine E. Kosmas, M.D., Ph.D.  
168-24 Powells Cove Blvd.  
Beechhurst, NY 11357  
E-mail: cekosmas1@gmail.com

August 22, 2019

Ying Dou  
Science Editor, Editorial Office  
Baishideng Publishing Group Inc

**RE: Manuscript entitled " Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease"**

Dear Mr. Dou,

My co-authors and I received the review of the above referenced manuscript. We are very appreciative of the time and effort that you have dedicated to our manuscript. Additionally, we greatly appreciate the constructive comments of the reviewers and believe they have identified areas where improvement was possible. Please find our itemized responses below in order of the reviewer's comments. In addition, our responses to the Revising Editor's comments are also included.

**Reviewers' Comments to Author:**

**Reviewer #1**

**Comments to Author:**

1. "This is an excellent editorial about various lipid-modifying therapies in cardiovascular disease. This manuscript is nicely structured and well written. I have one minor comment about this manuscript. (Comment) 1. Page 1, Abstract, line 2 Correct "dyslipidemia is on of the major risk factors" to "dyslipidemia is one of the major risk factors."

We would like to thank the reviewer for his nice comments regarding our manuscript. The specified error pinpointed by the reviewer was corrected in the revised manuscript.

**Reviewer #2**

**Comments to Author:**

1. "A list of abbreviation might help the reader."

We concur with the reviewer's comment and a list of the abbreviations used was added at the end of the revised manuscript, immediately after the "Conclusion".

**2. "A table to summarize the effects and mechanisms of action for each novel medication should be added."**

We concur with the reviewer's comment and a table (Table 1), entitled "Mechanisms of action of novel lipid-modifying therapies addressing unmet needs in cardiovascular disease", was added in the revised manuscript, exactly as requested by the reviewer. Reference to Table 1 was made in the last paragraph of the section entitled "Medications that decrease lipoprotein (a) levels" in the revised manuscript.

**3. "A figure to explain the different pathways involved significantly increase the impact of the paper."**

We concur with the reviewer's comment and a figure (Figure 1), entitled "Molecular pathways of action and effects of novel lipid-modifying therapies addressing unmet needs in cardiovascular disease", was added in the revised manuscript, exactly as requested by the reviewer. Reference to Figure 1 was also made in the last paragraph of the section entitled "Medications that decrease lipoprotein (a) levels" in the revised manuscript.

### **Reviewer #3**

#### **Comments to Author:**

**1. "One figure or table to summarize the mechanisms of action or the results of the new drugs could be nice to add."**

We concur with the reviewer's comment and, as mentioned above, a table (Table 1), entitled "Mechanisms of action of novel lipid-modifying therapies addressing unmet needs in cardiovascular disease", as well as a figure (Figure 1), entitled "Molecular pathways of action and effects of novel lipid-modifying therapies addressing unmet needs in cardiovascular disease", were added in the revised manuscript, exactly as requested by the reviewer. References to Table 1 and Figure 1 were made in the last paragraph of the section entitled "Medications that decrease lipoprotein (a) levels" in the revised manuscript.

### **Reviewer #4**

#### **Comments to Author:**

**1. "The authors had better provide a table of novel lipid-lowering therapy to make the readers to understand them easily."**

Again, we concur with the reviewer's comment and, as mentioned above, a table (Table 1), entitled "Mechanisms of action of novel lipid-modifying therapies addressing unmet needs in cardiovascular disease", was added in the revised manuscript, exactly as requested by the reviewer. Reference to Table 1 was made

in the last paragraph of the section entitled “Medications that decrease lipoprotein (a) levels” in the revised manuscript.

Furthermore, as per the Revising Editor’s request, we provided a short running title of our paper. The running title is “**Novel lipid therapies in cardiovascular disease**”. This running title was shown immediately below the main title in the revised manuscript.

Please also note that some typographical errors were corrected.

We much appreciate your consideration and sincerely hope that you find our manuscript now acceptable for publication in the “World Journal of Cardiology”.

Respectfully and on behalf of my co-authors,

Constantine E. Kosmas, M.D., Ph.D.